News from Rhythm A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

11 Apr, 2017, 08:00 ET Rhythm Appoints Head of Sanofi Genzyme, Dr. David Meeker, as Chairman of Board of Directors

Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies that result in life-threatening metabolic...


16 Feb, 2017, 08:31 ET Rhythm Announces Completion of $41 Million Mezzanine Financing

Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies that result in life-threatening metabolic...


04 Nov, 2016, 08:30 ET Rhythm Presents Positive Initial Data for Setmelanotide in LepR Deficiency Obesity

Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies that result in life-threatening metabolic...


19 Sep, 2016, 09:00 ET FierceBiotech Names Rhythm as a "Fierce 15" Biotechnology Company of 2016

Rhythm announced today that it has been named to the annual FierceBiotech "Fierce 15," designating Rhythm as one of the top privately held...


27 Jul, 2016, 08:00 ET Rhythm Announces "The Genetic Obesity Project" to Expand Understanding of Rare Genetic Disorders of Obesity

 Rhythm today announced "The Genetic Obesity Project" to improve the medical and scientific understanding of severe life-threatening obesity...


20 Jul, 2016, 17:00 ET Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity

Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies that result in life-threatening metabolic...


07 Jan, 2016, 08:45 ET Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity

 Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies that result in life-threatening metabolic...


07 Jan, 2016, 08:45 ET Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome

Rhythm announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for setmelanotide (RM-493), the...


05 Jan, 2016, 08:00 ET Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide

 Rhythm and Camurus announced today a license agreement for the use of Camurus' drug delivery technology, FluidCrystal®, to formulate...


16 Dec, 2015, 08:00 ET Rhythm Appoints David Meeker, MD, and David McGirr to Board of Directors

 Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic metabolic disorders, announced today that the company has...


06 Nov, 2015, 08:42 ET Rhythm Presents Cardiovascular Safety Data from Phase 1b/2a Clinical Trials of Setmelanotide in Obesity

Rhythm Pharmaceuticals, Inc. announced today the presentation of results from an evaluation of cardiovascular safety in three Phase 1b/2a clinical...


06 Nov, 2015, 08:40 ET Rhythm Presents Positive Data from Phase 1b Study of Setmelanotide for the Treatment of Genetic Obesity

 Rhythm Pharmaceuticals, Inc. announced today the results from a proof-of-concept, Phase 1b clinical trial assessing the safety and efficacy of...


11 Dec, 2014, 08:00 ET Rhythm Appoints Fred T. Fiedorek, M.D., Chief Medical Officer

 Rhythm announced today the appointment of Fred T. Fiedorek, MD, as Chief Medical Officer. In this position, Dr. Fiedorek will oversee clinical...


24 Oct, 2014, 08:00 ET Rhythm Presents Positive Phase 2 Study Results for Relamorelin for Chronic Constipation

Rhythm announced today the presentation of results from a Phase 2a clinical trial assessing the safety and efficacy of relamorelin (RM-131) in 48...


22 Oct, 2014, 08:30 ET Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin

 Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced that...


23 Jun, 2014, 08:00 ET Rhythm Presents Clinical Data that RM-493 Increases Energy Expenditure in Obesity Study

 Rhythm announced today the presentation of results from a clinical trial that evaluated the effect of RM-493, the company's novel melanocortin...


06 May, 2014, 11:02 ET Rhythm Presents Positive GI Motility Results for Relamorelin (RM-131) in Phase 2 Chronic Constipation Study

Rhythm announced today the presentation of pharmacodynamic results from a Phase 2 clinical trial with relamorelin (RM-131) for the treatment of...


06 May, 2014, 11:00 ET Rhythm Presents Positive Phase 2 Study Results for Ghrelin Prokinetic Relamorelin (RM-131) in Diabetic Gastroparesis

 Rhythm announced today the presentation of results from a Phase 2 clinical trial assessing the safety and efficacy of relamorelin (RM-131) in...


24 Sep, 2013, 08:00 ET Rhythm Initiates Clinical Trial of RM-493 for Obesity Caused by Genetic Variant

 Rhythm announced today the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor...


10 Sep, 2013, 06:30 ET Rhythm Awarded $1.35 Million from The Michael J. Fox Foundation to Advance Clinical Development of RM-131 for Refractory Constipation in Parkinson's Disease

Rhythm announced today that The Michael J. Fox Foundation for Parkinson's Research (MJFF) has awarded a $1.35 million research grant to Rhythm to...


20 May, 2013, 08:30 ET Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes

Rhythm announced today the results of a second Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic...


20 May, 2013, 08:30 ET Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.

 Rhythm announced today the presentation of results from a new epidemiology study demonstrating a higher prevalence of gastroparesis symptoms...


16 Apr, 2013, 06:30 ET Rhythm Initiates Phase 2 Clinical Trial of Ghrelin Prokinetic RM-131 for Lower GI Functional Disorders

 Rhythm announced today the initiation of an additional Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the...


04 Jan, 2013, 07:00 ET Rhythm Initiates Phase 2 Clinical Trial of RM-493 for Obesity

 Rhythm announced today the initiation of a Phase 2 clinical trial with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for...


27 Nov, 2012, 06:30 ET Rhythm Expands Series B Financing to $33 Million; Adds Pfizer Ventures as an Investor

Rhythm announced today that the company has raised an additional $8 million to complete a $33 million Series B financing. The additional $8 million...